Q-omics provides the consensus-scored LYPD8 profile across patient tissues and cancer cell-line models. LYPD8 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, LYPD8 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, LYPD8 RNA expression shows 11,115 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight ACC, COAD, and TGCT as cancer lineages where LYPD8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LYPD8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LYPD8 survival associations across molecular data types. LYPD8 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LYPD8 RNA expression–survival associations across cancer types. High LYPD8 expression shows unfavorable associations in ACC, UCEC, LIHC, SARC and SCLC, but favorable associations in LAML. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for LYPD8 RNA expression.
This table summarizes LYPD8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 1. The strongest signals are observed in COAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for LYPD8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LYPD8 shows lower tumor expression in COAD, KICH, KIRC and KIRP and higher tumor expression in HNSC and LIHC. The COAD box plot shows higher LYPD8 RNA expression in normal versus tumor tissue (log2 FC = −3.890, t-test p < 0.001).
This table shows molecular features associated with LYPD8 in patient tissues and cancer cell lines. In patient samples, LYPD8 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, LYPD8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BREAST.
